1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cardiovascular conditions
  5. Embolism and thrombosis

Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism

Technology appraisal guidance [TA287] Published date: 26 June 2013

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
  • Overview
  • 1 Guidance
  • 2 The technology
  • 3 The manufacturer's submission
  • 4 Consideration of the evidence
  • 5 Implementation
  • 6 Recommendations for further research
  • 7 Related NICE guidance
  • 8 Review of guidance
  • 9 Appraisal Committee members and NICE project team
  • 10 Sources of evidence considered by the Committee
  • Changes after publication
  • About this guidance
Download guidance
  • Save
  • Save as PDF
  • Save as ePub
  • Save as eBook

Guidance

  • Next

1 Guidance

1 Guidance

1.1 Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.

  • National Institute for Health and Care Excellence (NICE)

  • Next